Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309367 | 1.00 | DGAT1 (0.48) | DGAT1 | |
| SCHEMBL14872842 | 0.85 | DGAT1 (0.48) | DGAT1 | |
| SCHEMBL30831522 | 0.85 | PTK2 (0.51) | DGAT1 | |
| SCHEMBL1181203 | 0.85 | PTK2 (0.51) | DGAT1 | |
| SCHEMBL25148808 | 0.84 | DGAT1 (0.50) | DGAT1 | |
| SCHEMBL30401343 | 0.84 | DGAT1 (0.50) | DGAT1 | |
| SCHEMBL1553789 | 0.84 | GSK3A (0.44) | DGAT1 | |
| SCHEMBL3804793 | 0.83 | DGAT1 (0.47) | DGAT1 | |
| SCHEMBL3411384 | 0.82 | DGAT1 (0.50) | DGAT1 | |
| SCHEMBL3853494 | 0.81 | DGAT1 (0.49) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-10-02 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| EP-4161641-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11584738-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-2318377-B1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH INC (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-2318377-B1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20130157976-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | CLAUS ECKHARD (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20120252760-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-7674801-B2 | Alkyl urea substituted pyridines | ASTRAZENECA AB (SE) | 2010-03-09 | — | — | US | disclosed |
| WO-2010014939-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010014939-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| EP-2102199-A1 | ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS | AstraZeneca AB (SE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008068470-A1 | ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008068470-A1 | ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | WO | disclosed |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584738-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | DGAT1 162/4885 |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | DGAT1 4787/4885 |
| US-20120252760-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | DGAT1 4787/4885 |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | MRPL21, NISCH, ABCB11 | DGAT1 2633/4885 |
| US-20130157976-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | DGAT1 4787/4885 |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | DGAT1 162/4885 |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | DGAT1 162/4885 |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | DGAT1 162/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | DGAT1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.